Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal Cancer

NCT04776590 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Esophagus Cancer
Neoadjuvant Therapy

Interventions

DRUG: Tislelizumab

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborators

[object Object]